SG11202103571XA - Compositions and methods for immunotherapy - Google Patents

Compositions and methods for immunotherapy

Info

Publication number
SG11202103571XA
SG11202103571XA SG11202103571XA SG11202103571XA SG11202103571XA SG 11202103571X A SG11202103571X A SG 11202103571XA SG 11202103571X A SG11202103571X A SG 11202103571XA SG 11202103571X A SG11202103571X A SG 11202103571XA SG 11202103571X A SG11202103571X A SG 11202103571XA
Authority
SG
Singapore
Prior art keywords
immunotherapy
compositions
methods
Prior art date
Application number
SG11202103571XA
Inventor
Amy Melissa Becker
Surbhi Goel
Sarah Hesse
Troy Aaron Luster
Birgit Schultes
Stephanie A Yazinski
Pooja Vinay
Original Assignee
Intellia Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Intellia Therapeutics Inc filed Critical Intellia Therapeutics Inc
Publication of SG11202103571XA publication Critical patent/SG11202103571XA/en

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/111—General methods applicable to biologically active non-coding nucleic acids
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/87—Introduction of foreign genetic material using processes not otherwise provided for, e.g. co-transformation
    • C12N15/90—Stable introduction of foreign DNA into chromosome
    • C12N15/902—Stable introduction of foreign DNA into chromosome using homologous recombination
    • C12N15/907—Stable introduction of foreign DNA into chromosome using homologous recombination in mammalian cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
    • A61K48/005—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy characterised by an aspect of the 'active' part of the composition delivered, i.e. the nucleic acid delivered
    • A61K48/0058—Nucleic acids adapted for tissue specific expression, e.g. having tissue specific promoters as part of a contruct
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1138—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against receptors or cell surface proteins
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/16—Hydrolases (3) acting on ester bonds (3.1)
    • C12N9/22—Ribonucleases RNAses, DNAses
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/10—Type of nucleic acid
    • C12N2310/20—Type of nucleic acid involving clustered regularly interspaced short palindromic repeats [CRISPRs]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/31—Chemical structure of the backbone
    • C12N2310/315—Phosphorothioates
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/321—2'-O-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00—Structure or type of the nucleic acid
    • C12N2310/30—Chemical structure
    • C12N2310/32—Chemical structure of the sugar
    • C12N2310/322—2'-R Modification
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2320/00—Applications; Uses
    • C12N2320/30—Special therapeutic applications
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2750/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssDNA viruses
    • C12N2750/00011—Details
    • C12N2750/14011—Parvoviridae
    • C12N2750/14111—Dependovirus, e.g. adenoassociated viruses
    • C12N2750/14141—Use of virus, viral particle or viral elements as a vector
    • C12N2750/14143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Organic Chemistry (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biotechnology (AREA)
  • General Health & Medical Sciences (AREA)
  • General Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Physics & Mathematics (AREA)
  • Cell Biology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
SG11202103571XA 2018-10-16 2019-10-15 Compositions and methods for immunotherapy SG11202103571XA (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201862746522P 2018-10-16 2018-10-16
US201862747037P 2018-10-17 2018-10-17
PCT/US2019/056399 WO2020081613A1 (en) 2018-10-16 2019-10-15 Compositions and methods for immunotherapy

Publications (1)

Publication Number Publication Date
SG11202103571XA true SG11202103571XA (en) 2021-05-28

Family

ID=68502008

Family Applications (1)

Application Number Title Priority Date Filing Date
SG11202103571XA SG11202103571XA (en) 2018-10-16 2019-10-15 Compositions and methods for immunotherapy

Country Status (15)

Country Link
US (1) US20210340530A1 (en)
EP (1) EP3867379A1 (en)
JP (1) JP2022512703A (en)
KR (1) KR20210091160A (en)
CN (1) CN113227374A (en)
AU (1) AU2019362879A1 (en)
BR (1) BR112021007025A2 (en)
CA (1) CA3116132A1 (en)
CO (1) CO2021006301A2 (en)
IL (1) IL282225A (en)
MX (1) MX2021004214A (en)
PH (1) PH12021550849A1 (en)
SG (1) SG11202103571XA (en)
TW (1) TW202035693A (en)
WO (1) WO2020081613A1 (en)

Families Citing this family (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2022094313A1 (en) * 2020-10-30 2022-05-05 Arbor Biotechnologies, Inc. Compositions comprising an rna guide targeting trac and uses thereof
AU2021396403A1 (en) 2020-12-11 2023-06-29 Intellia Therapeutics, Inc. Compositions and methods for reducing mhc class ii in a cell
KR20230124664A (en) 2020-12-23 2023-08-25 인텔리아 테라퓨틱스, 인크. Compositions and methods for reducing HLA-A in cells
EP4267723A1 (en) 2020-12-23 2023-11-01 Intellia Therapeutics, Inc. Compositions and methods for genetically modifying ciita in a cell
IL304069A (en) 2020-12-30 2023-08-01 Intellia Therapeutics Inc Engineered t cells
WO2022170194A2 (en) 2021-02-08 2022-08-11 Intellia Therapeutics, Inc. Lymphocyte activation gene 3 (lag3) compositions and methods for immunotherapy
WO2022170193A2 (en) 2021-02-08 2022-08-11 Intellia Therapeutics, Inc. T-cell immunoglobulin and mucin domain 3 (tim3) compositions and methods for immunotherapy
JP2024505672A (en) 2021-02-08 2024-02-07 インテリア セラピューティクス，インコーポレイテッド Natural killer cell receptor 2B4 compositions and methods for immunotherapy
CN117083292A (en) * 2021-04-02 2023-11-17 科济生物医药（上海）有限公司 CS1 engineered cells and compositions thereof
CN117940153A (en) 2021-08-24 2024-04-26 因特利亚治疗公司 Programmed cell death protein 1 (PD 1) compositions and methods for cell-based therapies
WO2023081200A2 (en) 2021-11-03 2023-05-11 Intellia Therapeutics, Inc. Cd38 compositions and methods for immunotherapy
WO2023148494A1 (en) * 2022-02-03 2023-08-10 University College Cardiff Consultants Limited Novel t-cell receptor
WO2023205148A1 (en) 2022-04-19 2023-10-26 Intellia Therapeutics, Inc. Chimeric antigen receptor compositions and uses
WO2023225670A2 (en) * 2022-05-20 2023-11-23 Tome Biosciences, Inc. Ex vivo programmable gene insertion
WO2023245108A2 (en) 2022-06-16 2023-12-21 Intellia Therapeutics, Inc. Compositions and methods for reducing mhc class i in a cell
WO2024006955A1 (en) 2022-06-29 2024-01-04 Intellia Therapeutics, Inc. Engineered t cells
WO2024088401A1 (en) * 2022-10-28 2024-05-02 CorrectSequence Therapeutics Co., Ltd Gene editing systems and methods for reducing immunogenicity and graft versus host response

Family Cites Families (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5585481A (en) 1987-09-21 1996-12-17 Gen-Probe Incorporated Linking reagents for nucleotide probes
US5378825A (en) 1990-07-27 1995-01-03 Isis Pharmaceuticals, Inc. Backbone modified oligonucleotide analogs
DK1695979T3 (en) 1991-12-24 2011-10-10 Isis Pharmaceuticals Inc Gapped modified oligonucleotides
WO1995032305A1 (en) 1994-05-19 1995-11-30 Dako A/S Pna probes for detection of neisseria gonorrhoeae and chlamydia trachomatis
US20140310830A1 (en) 2012-12-12 2014-10-16 Feng Zhang CRISPR-Cas Nickase Systems, Methods And Compositions For Sequence Manipulation in Eukaryotes
ES2576128T3 (en) 2012-12-12 2016-07-05 The Broad Institute, Inc. Modification by genetic technology and optimization of systems, methods and compositions for the manipulation of sequences with functional domains
IL308158A (en) 2012-12-17 2023-12-01 Harvard College Rna-guided human genome engineering
MX2015011955A (en) 2013-03-08 2016-04-07 Novartis Ag Lipids and lipid compositions for the delivery of active agents.
CA2906970C (en) * 2013-03-21 2021-05-18 Ospedale San Raffaele Srl Targeted disruption of t cell receptor genes using engineered zinc finger protein nucleases
CA2913830C (en) * 2013-05-29 2021-06-29 Cellectis Methods for engineering t cells for immunotherapy by using rna-guided cas nuclease system
US9840699B2 (en) 2013-12-12 2017-12-12 President And Fellows Of Harvard College Methods for nucleic acid editing
EP3083556B1 (en) 2013-12-19 2019-12-25 Novartis AG Lipids and lipid compositions for the delivery of active agents
EP3800248A3 (en) * 2014-04-18 2021-08-04 Editas Medicine, Inc. Crispr-cas-related methods, compositions and components for cancer immunotherapy
US20150376586A1 (en) 2014-06-25 2015-12-31 Caribou Biosciences, Inc. RNA Modification to Engineer Cas9 Activity
ES2841274T3 (en) 2014-08-04 2021-07-07 Hutchinson Fred Cancer Res T-cell immunotherapy specific for WT-1
EP3215168B1 (en) * 2014-10-31 2023-08-02 The Trustees of the University of Pennsylvania Altering gene expression in modified t cells and uses thereof
EP3858990A1 (en) 2015-03-03 2021-08-04 The General Hospital Corporation Engineered crispr-cas9 nucleases with altered pam specificity
EP4019635A1 (en) * 2015-03-25 2022-06-29 Editas Medicine, Inc. Crispr/cas-related methods, compositions and components
US20160348073A1 (en) * 2015-03-27 2016-12-01 President And Fellows Of Harvard College Modified t cells and methods of making and using the same
EP3277294B1 (en) * 2015-04-01 2024-05-15 Adaptive Biotechnologies Corp. Method of identifying human compatible t cell receptors specific for an antigenic target
JP2018536436A (en) * 2015-12-04 2018-12-13 ノバルティス アーゲー Compositions and methods for immuno-oncology
US11026969B2 (en) * 2015-12-23 2021-06-08 Fred Hutchinson Cancer Research Center High affinity T cell receptors and uses thereof
WO2017136794A1 (en) 2016-02-03 2017-08-10 Massachusetts Institute Of Technology Structure-guided chemical modification of guide rna and its applications
KR102587132B1 (en) * 2016-03-04 2023-10-11 에디타스 메디신, 인코포레이티드 Crispr-cpf1-related methods, compositions and components for cancer immunotherapy
KR102617874B1 (en) 2016-03-30 2023-12-22 인텔리아 테라퓨틱스, 인크. Lipid nanoparticle formulations for CRISPR/CAS components
IL267024B2 (en) 2016-12-08 2023-12-01 Intellia Therapeutics Inc MODIFIED GUIDE RNAs FOR GENOMIC EDITING
CN110268050A (en) * 2017-01-10 2019-09-20 综合医院公司 The application method of modified T cell and they
US10934336B2 (en) * 2017-04-13 2021-03-02 The Trustees Of The University Of Pennsylvania Use of gene editing to generate universal TCR re-directed T cells for adoptive immunotherapy
MX2020004541A (en) * 2017-10-30 2021-04-12 Pact Pharma Inc Primary cell gene editing.
CN109750035B (en) * 2017-11-02 2020-06-05 上海邦耀生物科技有限公司 sgRNA for targeting and guiding Cas9 protein to efficiently cleave TCR and B2M gene locus
CN107746831B (en) * 2017-11-07 2019-04-23 南京北恒生物科技有限公司 Universal CART/TCRT cell and its construction method with chemotherapeutic drug resistance

Also Published As

Publication number Publication date
EP3867379A1 (en) 2021-08-25
TW202035693A (en) 2020-10-01
CN113227374A (en) 2021-08-06
JP2022512703A (en) 2022-02-07
AU2019362879A1 (en) 2021-05-27
PH12021550849A1 (en) 2021-12-06
MX2021004214A (en) 2021-07-15
BR112021007025A2 (en) 2021-08-03
CO2021006301A2 (en) 2021-06-10
CA3116132A1 (en) 2020-04-23
KR20210091160A (en) 2021-07-21
WO2020081613A1 (en) 2020-04-23
US20210340530A1 (en) 2021-11-04
IL282225A (en) 2021-05-31

Similar Documents

Publication Publication Date Title
IL282225A (en) Compositions and methods for immunotherapy
EP3765608A4 (en) Gene-regulating compositions and methods for improved immunotherapy
IL288754A (en) Compositions and methods for cancer immunotherapy
IL277079A (en) Cartyrin compositions and methods for use
EP3589373A4 (en) Compositions and methods for immunotherapy
SG10202001869VA (en) Cd19 compositions and methods for immunotherapy
SG11201912010XA (en) Pde5 compositions and methods for immunotherapy
EP3765094A4 (en) Gene-regulating compositions and methods for improved immunotherapy
IL280134A (en) Anti-cd112r compositions and methods
IL253341B (en) Methods and compositions for combination immunotherapy
EP3493827A4 (en) Compositions and methods for immunotherapy
EP3286213A4 (en) Methods and compositions for combination immunotherapy
IL261316A (en) Compositions and methods for cd20 immunotherapy
EP3765092A4 (en) Gene-regulating compositions and methods for improved immunotherapy
EP3402495A4 (en) Methods and compositions for t-cell immunotherapy
IL268684A (en) Compositions and methods for immunooncology
IL283644A (en) Compositions and methods for immunotherapy
EP3500262A4 (en) Compositions and methods for cancer immunotherapy
SG11202104448WA (en) Compositions and methods
IL274524A (en) Compositions and methods for aquaculturing
IL283076A (en) Methods and compositions for cancer immunotherapy
IL286587A (en) D-metyrosine compositions and methods for preparing same
IL292872A (en) Compositions and methods for immunotherapy
IL265965A (en) Methods and compositions for tusc2 immunotherapy
EP3752194A4 (en) Compositions and methods for tumor immunotherapy